Literature DB >> 2040347

Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations.

J De Schepper1, I Dab, M P Derde, H Loeb.   

Abstract

In 48 patients (age 2-28 years) with documented cystic fibrosis, glucose tolerance was evaluated by means of an oral glucose tolerance test (OGTT) and repeated glycosylated haemoglobin (HbA1C) measurements. An impaired OGTT was found in 15 patients. Their degree of undernutrition and severity of lung and liver involvement were no different from those with normal glucose tolerance. The mean peak insulin concentration as well as the integrated insulin concentration during the OGTT were comparable with patients with normal glucose tolerance (GT) and those with an impaired tolerance (GI). The mean time to attain peak insulin levels was significantly delayed in the GI group. (117 min vs 86 min P less than 0.01). On initial testing, elevated HbA1C levels were found in 22 patients. Mean HbA1C levels in the GI group were higher than in the GT group (8.2% vs 7.5% P less than 0.01). The HbA1C levels at the moment of OGT testing were positively correlated with the glycaemic response during the OGTT. The repeated HbA1C measurements 1 year later were no different from the initial mean HbA1C values in both groups. Two GI patients with initial HbA1C levels of 7.5% and 11% respectively developed diabetes mellitus several months after testing. The need for serial HbA1C determinations in cystic fibrosis is questioned.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040347     DOI: 10.1007/bf02093718

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  Diabetes mellitus and cystic fibrosis of the pancreas. Laboratory and clinical observations.

Authors:  R C ROSAN; H SHWACHMAN; L I KULCZVCKI
Journal:  Am J Dis Child       Date:  1962-12

2.  Endogenous and exogenous insulin responses in patients with cystic fibrosis.

Authors:  E G Wilmshurst; J S Soeldner; D S Holsclaw; R L Kaufmann; H Shwachman; T T Aoki; R E Gleason
Journal:  Pediatrics       Date:  1975-01       Impact factor: 7.124

3.  Glucose tolerance and diabetes in chronic liver disease.

Authors:  C Megyesi; E Samols; V Marks
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

4.  Endocrine function of the pancreas in cystic fibrosis: evidence for an impaired glucagon and insulin response following arginine infusion.

Authors:  M Stahl; J Girard; M Rutishauser; P W Nars; K Zuppinger
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

5.  Blood glucose and serum insulin levels in children with cystic fibrosis.

Authors:  A D Milner
Journal:  Arch Dis Child       Date:  1969-06       Impact factor: 3.791

6.  Diabetes mellitus associated with cystic fibrosis.

Authors:  S M Finkelstein; C L Wielinski; G R Elliott; W J Warwick; J Barbosa; S C Wu; D J Klein
Journal:  J Pediatr       Date:  1988-03       Impact factor: 4.406

7.  Glucose tolerance and insulin receptor binding to monocytes and erythrocytes in patients with cystic fibrosis.

Authors:  O Andersen; S Garne; C Heilmann; K E Petersen; W Petersen; C Koch
Journal:  Acta Paediatr Scand       Date:  1988-01

8.  Glycosylated haemoglobin and glucose intolerance in cystic fibrosis.

Authors:  P R Stutchfield; S O'Halloran; J D Teale; D Isherwood; C S Smith; D Heaf
Journal:  Arch Dis Child       Date:  1987-08       Impact factor: 3.791

9.  Hemoglobin A1 and pancreatic beta cell function in cystic fibrosis.

Authors:  T Bistritzer; J Sack; A Eshkol; D Katznelson
Journal:  Isr J Med Sci       Date:  1983-07

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  1 in total

1.  Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.

Authors:  R W Holl; E Heinze; A Wolf; M Rank; W M Teller
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.